We are a medical device company developing and commercializing innovative technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms, or AAA. Our mission is to help physicians improve the lives of patients suffering from aortic disease through excellence in research, product development, manufacturing, sales and service. We developed our technology platform leveraging engineering principles utilized in many industries including aerospace, aircraft and automotive, and applied these concepts with the goal of designing an optimal solution for AAA therapy to address unmet clinical needs. The Ovation System, our solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a new stent graft platform, providing an innovative and effective alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. We estimate the global market for AAA stent grafts was approximately $1.5 billion in 2014 and expect it grow to approximately $1.8 billion in 2017. Improvements in EVAR technology, combined with its demonstrated safety and other advantages relative to open surgical repair, have led to EVAR generally becoming the preferred approach to AAA repair in the United States and many other countries. In the United States, it is reported that EVAR is used to treat approximately 70% of all patients receiving AAA repair. However, given the technical limitations of conventional EVAR devices and the variability in patient anatomy, no currently available commercial EVAR device can address 100% of AAA patients, and a significant number of patients diagnosed with AAA are ineligible for EVAR with conventional devices or are unable or unwilling to undergo an open surgical procedure and receive no AAA treatment at all.
Company profile
Ticker
TRIV
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Alibaba Group Holding Limited • 3M • GE HealthCare • Uber • The Kraft Heinz Company • Lineage • News • Boston Scientific • KE • American Water Works ...
Former names
TV2 Holding Co, TV2 HOLDING Co
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-12B
Securities registration termination
17 Feb 16
RW
Registration withdrawal request
5 Feb 16
RW
Registration withdrawal request
5 Feb 16
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Feb 16
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Feb 16
25-NSE
Exchange delisting
4 Feb 16
8-K
Endologix, Inc. and TriVascular Technologies, Inc. Complete Merger
3 Feb 16
DEFA14A
Additional proxy soliciting materials
26 Jan 16
425
Business combination disclosure
12 Jan 16
DEFM14A
Proxy related to merger
8 Jan 16
Latest ownership filings
SC 13D/A
TriVascular Technologies, Inc.
8 Apr 16
SC 13G/A
TriVascular Technologies, Inc.
10 Mar 16
SC 13G/A
TriVascular Technologies, Inc.
16 Feb 16
SC 13G/A
TriVascular Technologies, Inc.
16 Feb 16
SC 13G/A
TriVascular Technologies, Inc.
12 Feb 16
SC 13G/A
TriVascular Technologies, Inc.
11 Feb 16
SC 13D
TriVascular Technologies, Inc.
10 Feb 16
4
DOUGLAS A ROEDER
5 Feb 16
4
DAVID L DOUGLASS
5 Feb 16
4
SCOTT D SANDELL
4 Feb 16
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|